Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Safety and Efficacy Study of HLA-G- Targeted CAR-T Cells IVS-3001 in Subjects with Previously Treated Advanced HLA-G-Positive Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a, Safety and Efficacy Study of HLA-G- Targeted CAR-T Cells IVS-3001 in Subjects with Previously Treated Advanced HLA-G-Positive Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IVS-3001 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Carcinoma; Ovarian cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 11 Dec 2023 Planned End Date changed from 29 Jun 2029 to 29 Dec 2029.
  • 13 Jul 2023 According to an Invectys media release, company has initiated the clinical trial of its lead CAR-T program, IVS-3001.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top